Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904681 | 0.73 | GAA (0.46) | GAAMAPT | |
| SCHEMBL6607968 | 0.73 | GAA (0.46) | GAAMAPTALDH1A1 | |
| SCHEMBL20338456 | 0.69 | MAPT (0.42) | GAAMAPTSMN1; SMN2 | |
| SCHEMBL2255782 | 0.69 | MAPT (0.50) | GAAMAPTP2RX4ALDH1A1SMN1; SMN2 | |
| SCHEMBL29789697 | 0.69 | MAPT (0.50) | GAAMAPTP2RX4ALDH1A1SMN1; SMN2 | |
| SCHEMBL7597347 | 0.68 | GAA (0.37) | GAAMAPTP2RX4 | |
| SCHEMBL9293762 | 0.67 | GAA (0.43) | GAAMAPT | |
| SCHEMBL20338470 | 0.67 | GAA (0.39) | GAAMAPT | |
| SCHEMBL21145451 | 0.66 | GAA (0.46) | GAAMAPTALDH1A1 | |
| SCHEMBL1285713 | 0.66 | MAPT (0.46) | GAAMAPTP2RX4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-10-11 | — | — | US | disclosed |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | NATIONAL CANCER CENTER (KR) | 2021-10-14 | — | — | US | disclosed |
| US-10227306-B2 | Compounds for inhibiting c-myc/max/DNA complex formation | NATIONAL CANCER CENTER (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180186744-A1 | COMPOUNDS FOR INHIBITING C-MYC/MAX/DNA COMPLEX FORMATION | NATIONAL CANCER CENTER (KR) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | MYC, MYCBP, TP53 | GAA 1125/4885MAPT 848/4885P2RX4 4873/4885 |
| US-10227306-B2 | Compounds for inhibiting c-myc/max/DNA complex formation | MYC, MYCBP, MYCBP2 | GAA 1908/4885MAPT 2894/4885P2RX4 4876/4885 |
| US-20180186744-A1 | COMPOUNDS FOR INHIBITING C-MYC/MAX/DNA COMPLEX FORMATION | MYC, MYCBP, MYCBP2 | GAA 1908/4885MAPT 2894/4885P2RX4 4876/4885 |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | MYC, MYCBP, TP53 | GAA 1125/4885MAPT 848/4885P2RX4 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.